Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
1999-05-06
2003-08-19
Baker, Maurie (Department: 1639)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S310000, C546S139000, C546S144000, C546S150000
Reexamination Certificate
active
06608082
ABSTRACT:
FIELD OF THE INVENTION
The present invention relates generally to the fields of medicinal chemistry and molecular pathology and, more specifically, to novel isoquinoline compounds and their use as melanocortin receptor ligands and as agents for controlling cytokine-regulated physiologic processes and pathologies, as well as combinatorial libraries comprising such compounds.
BACKGROUND INFORMATION
The melanocortin (MC) receptors are a group of cell surface proteins that mediate a variety of physiological effects, including regulation of adrenal gland function such as production of the glucocorticoids cortisol and aldosterone; control of melanocyte growth and pigment production; thermoregulation; immunomodulation; and analgesia. Five distinct MC receptors have been cloned and are expressed in a variety of tissues, including melanocytes, adrenal cortex, brain, gut, placenta, skeletal muscle, lung, spleen, thymus, bone marrow, pituitary, gonads and adipose tissue (Tatro,
Neuroimmunomodulation
3:259-284 (1996)). Three MC receptors, MCR-1, MCR-3 and MCR-4, are expressed in brain tissue (Xia et al.,
Neuroreport
6:2193-2196 (1995)).
A variety of ligands termed melanocortins function as agonists that stimulate the activity of MC receptors. The melanocortins include melanocyte-stimulating hormones (MSH) such as &agr;-MSH, &bgr;-MSH and &ggr;-MSH, as well as adrenocorticotropic hormone (ACTH). Individual ligands can bind to multiple MC receptors with differing relative affinities. The variety of ligands and MC receptors with differential tissue-specific expression likely provides the molecular basis for the diverse physiological effects of melanocortins and MC receptors. For example, &agr;-MSH antagonizes the actions of immunological substances such as cytokines and acts to modulate fever, inflammation and immune responses (Catania and Lipton,
Annals N. Y. Acad. Sci.
680:412-423 (1993)).
More recently, the role of specific MC receptors in some of the physiological effects described above for MC receptors has been elucidated. For example, MCR-1 is involved in pain and inflammation. MCR-1 mRNA is expressed in neutrophils (Catania et al.,
Peptides
17:675-679 (1996)). The anti-inflammatory agent &agr;-MSH was found to inhibit migration of neutrophils. Thus, the presence of MCR-1 in neutrophils correlates with the anti-inflammatory activity of &agr;-MSH.
An interesting link of MC receptors to regulation of food intake and obesity has recently been described. The brain MC receptor MCR-4 has been shown to function in the regulation of body weight and food intake. Mice in which MCR-4 has been knocked out exhibit weight gain (Huszar et al.,
Cell
88:131-141 (1997)). In addition, injection into brain of synthetic peptides that mimic melanocortins and bind to MCR-4 caused suppressed feeding in normal and mutant obese mice (Fan et al.,
Nature
385:165-168 (1997)). These results indicate that the brain MC receptor MCR-4 functions in regulating food intake and body weight.
Due to the varied physiological activities of MC receptors, high affinity ligands of MC receptors could be used to exploit the varied physiological responses of MC receptors by functioning as potential therapeutic agents or as lead compounds for the development of therapeutic agents. Furthermore, due to the effect of MC receptors on the activity of various cytokines, high affinity MC receptor ligands could also be used to regulate cytokine activity.
Thus, there exists a need for ligands that bind to MC receptors with high affinity for use in altering MC receptor activity. The present invention satisfies this need and provides related advantages as well.
SUMMARY OF THE INVENTION
The invention provides melanocortin receptor ligands and methods of using the ligands to alter or regulate the activity of a melanocortin receptor. The invention further relates to tetrahydroisoquinoline aromatic amines that function as melanocortin receptor ligands.
REFERENCES:
patent: 5010175 (1991-04-01), Rutter et al.
patent: 5182366 (1993-01-01), Huebner et al.
patent: 5288514 (1994-02-01), Ellman
patent: 5324483 (1994-06-01), Cody et al.
patent: 5420109 (1995-05-01), Suto et al.
patent: 5439938 (1995-08-01), Snyder et al.
patent: 5576290 (1996-11-01), Hadley
patent: 5618791 (1997-04-01), Du
patent: 5726156 (1998-03-01), Girten et al.
patent: 5731408 (1998-03-01), Hadley et al.
patent: 5837521 (1998-11-01), Cone et al.
patent: 5874443 (1999-02-01), Kiely et al.
patent: 5889056 (1999-03-01), Hodson et al.
patent: 5916899 (1999-06-01), Kiely et al.
patent: 6054556 (2000-04-01), Huby et al.
patent: 6100048 (2000-08-01), Cone et al.
patent: 6127381 (2000-10-01), Basu et al.
patent: 0 590 455 (1993-09-01), None
patent: WO 91/19735 (1991-12-01), None
patent: WO 94/01102 (1994-01-01), None
patent: WO 95/02566 (1995-01-01), None
patent: WO 95/04277 (1995-02-01), None
patent: WO 95/13086 (1995-05-01), None
patent: WO 96/27386 (1996-09-01), None
patent: WO 97/22356 (1997-06-01), None
Schiöth et al., “Characterization of the binding of MSH-B, HP-228, GHRP-6 and 153N-6 to the human melanocortin receptor subtypes,”Neuropeptides, 31:565-571 (1997).
Abou-Mohamed et al., “HP-228, a novel synthetic peptide, inhibits the induction of nitric oxide synthase in vivo but not in vitro,”J. Pharmacology Experimental Therapeutics, 275:584-591 (1995).
Berge et al., “Pharmaceutical salts,”J. Pharm. Sci., 66:1-19 (1977).
Castagnoli, “The condensation of succinic anhydride with benzylidinemethylamine. A stereoselective synthesis of trans- and cis-1-Methyl-4-carboxy-5-phenyl-2-pyrrolidinone.”J. of Org. Chem., 34(10) :3187-3189 (1969).
Catania and Lipton, “&agr;-Melanocyte-Stimulating Hormone Peptides in Host Response, From Basic Evidence to Human Research,”Annals N.Y. Acad.Sci., 680:412-423 (1993).
Catania et al., “The Neuropeptide &agr;-MSH Has Specific Receptors on Neutrophils and Reduces Chemotaxis In Vitro,”Peptides, 17(4):675-679 (1996).
Chowdhary et al., “Localization of the human melanocortin-5 receptor gene (MC5R) to chromosomes band 18p11.2 by fluorescence in situ hybridization,”Cytogenet. Cell Genet.68:79-81 (1995).
Coppola, Gary, “Novel heterocycles. 8. Fused isoquinolines derived from the reaction of homophthalic anhydride with cyclic imino ethers.”J. Heterocyclic Chem., 18:767-770 (1981).
Cushman and Castagnoli, “The synthesis oftrans-3-methylnicotine.”J. Org. Chem., 37(8):1268-1271 (1972).
Cushman and Castagnoli, “Synthesis of pharmacologically active nitrogen analogs of the tetrahydrocannabinols.”J. Org. Chem., 39(11):1546-1550 (1974).
Cushman and Castagnoli, “The condensation of succinic anhydrides with schiff bases. Scope and mechanism.”J. Org. Chem., 36(22):3404-3406 (1971).
Cushman and Castagnoli, “A novel approach to the synthesis of nitrogen analogs of the tetrahydrocannabinols.”J. Org. Chem., 38(3):440-448 (1973).
Cushman and Madaj, “A study and mechanistic interpretation of the electronic and steric effects that determine the stereochemical outcome of the reaction of schiff bases with homophthalic anhydride and a 3-phenylsuccinic anhydride.”J. Org. Chem., 52(5):907-915 (1987).
Dooley et al., “Melanocortin receptor binding assay in rat brain homogenate: identification of tetrapeptide ligands from a combinatorial library,”Society for Neuroscience23:964 Abstract 383.18 (Aug. 21, 1997).
Dorr et al., “Evaluation of melanotan-II, a superpotent cyclic melanotropic peptide in a pilot phase-I clinical study,”Life Sci., 58(20):1777-1784 (1996).
Fan et al., “Role of melanocortinergic neurons in feeding and the agouti obesity syndrome,”Nature, 385:165-168 (1997).
Frandberg et al., “Glutamine235and arginine272in human melanocortin 5 receptor determines its low affinity to MSH,”Biochem. Biophys. Res. Commun.236:489-492 (1997).
Friedman, “The alphabet of weight control,”Nature, 385:119-120 (1997).
Gallop et al., “Applications of Combinatorial Technologies to Drug Discovery. 1. Background and Peptide Combinatorial Libraries,”J. Med. Chem., 37:1233-1251 (1994).
Gantz et al., “Molecular cloning, expression, and gene localization of a fourth melancortin receptor,”J. B
Basu Amaresh
Gahman Timothy C.
Girten Beverly E.
Griffith Michael C.
Hecht Curtis C.
Baker Maurie
Lion Bioscience AG
McDermott & Will & Emery
LandOfFree
Treatment of erectile dysfunction using isoquinoline... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Treatment of erectile dysfunction using isoquinoline..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Treatment of erectile dysfunction using isoquinoline... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3106920